- Home
- AEF vs RCEL Comparison
AEF vs RCEL Comparison
Compare AEF & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEF
- RCEL
- Stock Information
- Founded
- AEF 1989
- RCEL N/A
- Country
- AEF United States
- RCEL United States
- Employees
- AEF N/A
- RCEL N/A
- Industry
- AEF Finance/Investors Services
- RCEL Medical/Dental Instruments
- Sector
- AEF Finance
- RCEL Health Care
- Exchange
- AEF Nasdaq
- RCEL Nasdaq
- Market Cap
- AEF 196.1M
- RCEL 161.5M
- IPO Year
- AEF N/A
- RCEL N/A
- Fundamental
- Price
- AEF $5.94
- RCEL $5.35
- Analyst Decision
- AEF
- RCEL Strong Buy
- Analyst Count
- AEF 0
- RCEL 4
- Target Price
- AEF N/A
- RCEL $16.50
- AVG Volume (30 Days)
- AEF 92.5K
- RCEL 326.4K
- Earning Date
- AEF 01-01-0001
- RCEL 08-07-2025
- Dividend Yield
- AEF 7.13%
- RCEL N/A
- EPS Growth
- AEF N/A
- RCEL N/A
- EPS
- AEF 0.57
- RCEL N/A
- Revenue
- AEF N/A
- RCEL $71,661,000.00
- Revenue This Year
- AEF N/A
- RCEL $57.16
- Revenue Next Year
- AEF N/A
- RCEL $36.69
- P/E Ratio
- AEF $8.86
- RCEL N/A
- Revenue Growth
- AEF N/A
- RCEL 41.35
- 52 Week Low
- AEF $4.40
- RCEL $4.71
- 52 Week High
- AEF $5.53
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- AEF 67.14
- RCEL 34.33
- Support Level
- AEF $5.51
- RCEL $4.71
- Resistance Level
- AEF $5.77
- RCEL $5.45
- Average True Range (ATR)
- AEF 0.08
- RCEL 0.33
- MACD
- AEF 0.00
- RCEL 0.01
- Stochastic Oscillator
- AEF 95.00
- RCEL 25.31
About AEF abrdn Emerging Markets Equity Income Fund Inc.
ABERDEEN EMERGING MARKETS EQUITY INCOME FUND, INC. is a closed-end investment company. The Fund's investment objective is to seek to provide both current income and long-term capital appreciation. The Fund invests in a range of sectors, including financials, consumer staples, utilities, consumer discretionary, materials, energy, information technology, private equity, communication services, healthcare, real estate, and industrials.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.